KSHV LANA—The Master Regulator of KSHV Latency

Viruses

Volumn 6, Issue 12, 2014, Pages 4691-4998

  Uppal, Timsy ^a   Banerjee, Sagarika ^b   Sun, Zhiguo ^b   Verma, Subhash C ^a   Robertson, Erle S ^b  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

DNA replication; reactivation; Kaposi s sarcoma associated herpesvirus; KS; KSHV; Minichromosome; Signaling

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; AURORA B KINASE; BONE MORPHOGENETIC PROTEIN; BROMODOMAIN AND EXTRA TERMINAL PROTEIN; CAPSID PROTEIN; CASPASE 3; CASPASE 7; CENTROMERE PROTEIN F; DNA TOPOISOMERASE (ATP HYDROLYSING); FLICE INHIBITORY PROTEIN; GLYCOGEN SYNTHASE KINASE 3; H2 ANTIGEN; HISTONE DEACETYLASE 1; HISTONE H2B; INTERFERON REGULATORY FACTOR 3; LATENCY ASSOCIATED NUCLEAR ANTIGEN; METHYL CPG BINDING PROTEIN 2; MICRORNA; MINICHROMOSOME MAINTENANCE PROTEIN; MINICHROMOSOME MAINTENANCE PROTEIN 3; NUCLEIC ACID BINDING PROTEIN; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN ARGININE METHYLTRANSFERASE 1; PROTEIN P53; REPLICATION FACTOR C; SMAD1 PROTEIN; STAT3 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS RNA;

ANGIOGENESIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CHROMATIN STRUCTURE; CHROMOSOMAL INSTABILITY; DNA METHYLATION; DNA REPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIGENETICS; EPISOME; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE ONTOLOGY; HUMAN; HUMAN HERPESVIRUS 8; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LIFE CYCLE ASSESSMENT; M PHASE CELL CYCLE CHECKPOINT; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; VIRUS GENE; VIRUS LATENCY; VIRUS REPLICATION; WNT SIGNALING PATHWAY; X RAY DIFFRACTION; XENOPUS LAEVIS;

HERPESVIRIDAE; HUMAN HERPESVIRUS 8; SIMPLEXVIRUS;

EID: 84916881756     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v6124961     Document Type: Article

References (219)

1. Sturzl, M.; Zietz, C.; Monini, P.; Ensoli, B. Human herpesvirus-8 and Kaposi’s sarcoma: Relationship with the multistep concept of tumorigenesis. Adv. Cancer Res. 2001, 81, 125–159.
2. Chang, Y.; Cesarman, E.; Pessin, M.S.; Lee, F.; Culpepper, J.; Knowles, D.M.; Moore, P.S. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science1994, 266, 1865–1869.
3. Boshoff, C.; Chang, Y. Kaposi’s sarcoma-associated herpesvirus: A new DNA tumor virus. Annu. Rev. Med. 2001, 52, 453–470.
4. Whitby, D.; Howard, M.R.; Tenant-Flowers, M.; Brink, N.S.; Copas, A.; Boshoff, C.; Hatzioannou, T.; Suggett, F.E.; Aldam, D.M.; Denton, A.S.; et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi’s sarcoma. Lancet1995, 346, 799–802.
5. Gao, S.J.; Kingsley, L.; Hoover, D.R.; Spira, T.J.; Rinaldo, C.R.; Saah, A.; Phair, J.; Detels, R.; Parry, P.; Chang, Y.; et al. Seroconversion to antibodies against Kaposi’s sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi’s sarcoma. N. Engl. J. Med. 1996, 335, 233–241.
6. Martin, J.N.; Ganem, D.E.; Osmond, D.H.; Page-Shafer, K.A.; Macrae, D.; Kedes, D.H. Sexual transmission and the natural history of human herpesvirus 8 infection. N. Engl. J. Med. 1998, 338, 948–954.
7. Cesarman, E.; Chang, Y.; Moore, P.S.; Said, J.W.; Knowles, D.M. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 1995, 332, 1186–1191.
8. Soulier, J.; Grollet, L.; Oksenhendler, E.; Cacoub, P.; Cazals-Hatem, D.; Babinet, P.; d’Agay, M.F.; Clauvel, J.P.; Raphael, M.; Degos, L.; et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood1995, 86, 1276–1280.
9. Gill, P.S.; Tsai, Y.C.; Rao, A.P.; Spruck, C.H., 3rd; Zheng, T.; Harrington, W.A., Jr.; Cheung, T.; Nathwani, B.; Jones, P.A. Evidence for multiclonality in multicentric Kaposi’s sarcoma. Proc. Natl. Acad. Sci. USA1998, 95, 8257–8261.
10. Gessain, A.; Duprez, R. Spindle cells and their role in Kaposi’s sarcoma. Int. J. Biochem. Cell Biol. 2005, 37, 2457–2465.
11. Ambroziak, J.A.; Blackbourn, D.J.; Herndier, B.G.; Glogau, R.G.; Gullett, J.H.; McDonald, A.R.; Lennette, E.T.; Levy, J.A. Herpes-like sequences in HIV-infected and uninfected Kaposi’s sarcoma patients. Science1995, 268, 582–583.
12. Uldrick, T.S.; Wang, V.; O’Mahony, D.; Aleman, K.; Wyvill, K.M.; Marshall, V.; Steinberg, S.M.; Pittaluga, S.; Maric, I.; Whitby, D.; et al. An Interleukin-6-Related Systemic Inflammatory Syndrome in Patients Co-Infected with Kaposi Sarcoma-Associated Herpesvirus and HIV but without Multicentric Castleman Disease. Clin. Infect. Dis. 2010, 51, 350–358.
13. Holkova, B.; Takeshita, K.; Cheng, D.M.; Volm, M.; Wasserheit, C.; Demopoulos, R.; Chanan-Khan, A. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi’s sarcoma treated with chemotherapy. J. Clin. Oncol. 2001, 19, 3848–3851.
14. Martin, J.N. The epidemiology of KSHV and its association with malignant disease. In Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis; Arvin, A., Campadelli-Fiume, G., Mocarski, E., Moore, P.S., Roizman, B., Whitley, R., Yamanishi, K., Eds.; Cambridge University Press: Cambridge, UK, 2007.
15. Dourmishev, L.A.; Dourmishev, A.L.; Palmeri, D.; Schwartz, R.A.; Lukac, D.M. Molecular genetics of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. Microbiol. Mol. Biol. Rev. 2003, 67, 175–212.
16. Gao, S.J.; Kingsley, L.; Li, M.; Zheng, W.; Parravicini, C.; Ziegler, J.; Newton, R.; Rinaldo, C.R.; Saah, A.; Phair, J.; et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi’s sarcoma. Nat. Med. 1996, 2, 925–928.
17. Kedes, D.H.; Operskalski, E.; Busch, M.; Kohn, R.; Flood, J.; Ganem, D. The seroepidemiology of human herpesvirus 8 (Kaposi Kaposi’s sarcoma-associated herpesvirus): Distribution of infection in KS risk groups and evidence for sexual transmission. Nat. Med. 1996, 2, 918–924.
18. Simpson, G.R.; Schulz, T.F.; Whitby, D.; Cook, P.M.; Boshoff, C.; Rainbow, L.; Howard, M.R.; Gao, S.J.; Bohenzky, R.A.; Simmonds, P.; et al. Prevalence of Kaposi’s sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet1996, 348, 1133–1138.
19. Dukers, N.H.; Rezza, G. Human herpesvirus 8 epidemiology: What we do and do not know. AIDS 2003, 17, 1717–1730.
20. Hayward, G.S. KSHV strains: The origins and global spread of the virus. Semin. Cancer Biol. 1999, 9, 187–199.
21. Hayward, G.S.; Zong, J.C. Modern evolutionary history of the human KSHV genome. Curr. Top. Microbiol. Immunol. 2007, 312, 1–42.
22. Stebbing, J.; Bourboulia, D.; Johnson, M.; Henderson, S.; Williams, I.; Wilder, N.; Tyrer, M.; Youle, M.; Imami, N.; Kobu, T.; et al. Kaposi’s sarcoma-associated herpesvirus cytotoxic T lymphocytes recognize and target Darwinian positively selected autologous K1 epitopes. J. Virol. 2003, 77, 4306–4314.
23. Poole, L.J.; Zong, J.C.; Ciufo, D.M.; Alcendor, D.J.; Cannon, J.S.; Ambinder, R.; Orenstein, J.M.; Reitz, M.S.; Hayward, G.S. Comparison of genetic variability at multiple loci across the genomes of the major subtypes of Kaposi’s sarcoma-associated herpesvirus reveals evidence for recombination and for two distinct types of open reading frame K15 alleles at the right-hand end. J. Virol. 1999, 73, 6646–6660.
24. Zong, J.; Ciufo, D.M.; Viscidi, R.; Alagiozoglou, L.; Tyring, S.; Rady, P.; Orenstein, J.; Boto, W.; Kalumbuja, H.; Romano, N.; et al. Genotypic analysis at multiple loci across Kaposi’s sarcoma herpesvirus (KSHV) DNA molecules: Clustering patterns, novel variants and chimerism. J. Clin. Virol. 2002, 23, 119–148.
25. Vitale, F.; Viviano, E.; Perna, A.M.; Bonura, F.; Mazzola, G.; Ajello, F.; Romano, N. Serological and virological evidence of non-sexual transmission of human herpesvirus type 8 (HHV8). Epidemiol. Infect. 2000, 125, 671–675.
26. Sitas, F.; Newton, R. Kaposi’s sarcoma in South Africa. J. Natl. Cancer Inst. Monogr. 2001, 28, 1–4.
27. Bagni, R.; Whitby, D. Kaposi’s sarcoma-associated herpesvirus transmission and primary infection. Curr. Opin. HIV AIDS2009, 4, 22–26.
28. Vieira, J.; Huang, M.L.; Koelle, D.M.; Corey, L. Transmissible Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in saliva of men with a history of Kaposi’s sarcoma. J. Virol. 1997, 71, 7083–7087.
29. Farge, D.; Lebbe, C.; Marjanovic, Z.; Tuppin, P.; Mouquet, C.; Peraldi, M.N.; Lang, P.; Hiesse, C.; Antoine, C.; Legendre, C.; et al. Human herpes virus-8 and other risk factors for Kaposi’s sarcoma in kidney transplant recipients. Groupe Cooperatif de Transplantation d’Ile de France (GCIF). Transplantation1999, 67, 1236–1242.
30. Garcia-Astudillo, L.A.; Leyva-Cobian, F. Human herpesvirus-8 infection and Kaposi’s sarcoma after liver and kidney transplantation in different geographical areas of Spain. Transpl. Immunol. 2006, 17, 65–69.
31. Hladik, W.; Dollard, S.C.; Mermin, J.; Fowlkes, A.L.; Downing, R.; Amin, M.M.; Banage, F.; Nzaro, E.; Kataaha, P.; Dondero, T.J.; et al. Transmission of human herpesvirus 8 by blood transfusion. N. Engl. J. Med. 2006, 355, 1331–1338.
32. Russo, J.J.; Bohenzky, R.A.; Chien, M.C.; Chen, J.; Yan, M.; Maddalena, D.; Parry, J.P.; Peruzzi, D.; Edelman, I.S.; Chang, Y.; et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc. Natl. Acad. Sci. USA1996, 93, 14862–14867.
33. Ohsaki, E.; Ueda, K. Kaposi’s Sarcoma-Associated Herpesvirus Genome Replication, Partitioning, and Maintenance in Latency. Front. Microbiol. 2012, 3, 7.
34. Toth, Z.; Brulois, K.; Jung, J.U. The chromatin landscape of Kaposi’s sarcoma-associated herpesvirus. Viruses2013, 5, 1346–1373.
35. Fukumoto, H.; Kanno, T.; Hasegawa, H.; Katano, H. Pathology of Kaposi’s Sarcoma-Associated Herpesvirus Infection. Front. Microbiol. 2011, 2, 175.
36. Yu, Y.; Black, J.B.; Goldsmith, C.S.; Browning, P.J.; Bhalla, K.; Offermann, M.K. Induction of human herpesvirus-8 DNA replication and transcription by butyrate and TPA in BCBL-1 cells. J. Gen. Virol. 1999, 80, 83–90.
37. Lieberman, P.M. Keeping it quiet: Chromatin control of gammaherpesvirus latency. Nat. Rev. Microbiol. 2013, 11, 863–875.
38. Cai, Q.; Verma, S.C.; Lu, J.; Robertson, E.S. Molecular biology of Kaposi’s sarcoma-associated herpesvirus and related oncogenesis. Adv. Virus Res. 2010, 78, 87–142.
39. Davis, D.A.; Rinderknecht, A.S.; Zoeteweij, J.P.; Aoki, Y.; Read-Connole, E.L.; Tosato, G.; Blauvelt, A.; Yarchoan, R. Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood2001, 97, 3244–3250.
40. Ye, F.; Zhou, F.; Bedolla, R.G.; Jones, T.; Lei, X.; Kang, T.; Guadalupe, M.; Gao, S.J. Reactive oxygen species hydrogen peroxide mediates Kaposi’s sarcoma-associated herpesvirus reactivation from latency. PLoS Pathog. 2011, 7, e1002054.
41. Xie, J.; Ajibade, A.O.; Ye, F.; Kuhne, K.; Gao, S.J. Reactivation of Kaposi’s sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways. Virology2008, 371, 139–154.
42. Li, Q.; He, M.; Zhou, F.; Ye, F.; Gao, S.J. Activation of Kaposi’s sarcoma-associated herpesvirus (KSHV) by inhibitors of class III histone deacetylases: Identification of sirtuin 1 as a regulator of the KSHV life cycle. J. Virol. 2014, 88, 6355–6367.
43. Pantry, S.N.; Medveczky, P.G. Epigenetic regulation of Kaposi’s sarcoma-associated herpesvirus replication. Semin. Cancer Biol. 2009, 19, 153–157.
44. Jenner, R.G.; Alba, M.M.; Boshoff, C.; Kellam, P. Kaposi’s sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays. J. Virol. 2001, 75, 891–902.
45. Polizzotto, M.N.; Uldrick, T.S.; Hu, D.; Yarchoan, R. Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV-MCD) and the KSHV Inflammatory Cytokine Syndrome. Front. Microbiol. 2012, 3, 73.
46. Chang, H.H.; Ganem, D. A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and rapamycin sensitivity. Cell Host Microbe2013, 13, 429–440.
47. Yogev, O.; Boshoff, C. Redefining KSHV latency. Cell Host Microbe2013, 13, 373–374.
48. Arias, C.; Weisburd, B.; Stern-Ginossar, N.; Mercier, A.; Madrid, A.S.; Bellare, P.; Holdorf, M.; Weissman, J.S.; Ganem, D. KSHV 2.0: A comprehensive annotation of the Kaposi’s sarcoma-associated herpesvirus genome using next-generation sequencing reveals novel genomic and functional features. PLoS Pathog. 2014, 10, e1003847.
49. Speck, S.H.; Ganem, D. Viral latency and its regulation: Lessons from the gamma-herpesviruses. Cell Host Microbe2010, 8, 100–115.
50. Burysek, L.; Pitha, P.M. Latently expressed human herpesvirus 8-encoded interferon regulatory factor 2 inhibits double-stranded RNA-activated protein kinase. J. Virol. 2001, 75, 2345–2352.
51. Dittmer, D.; Lagunoff, M.; Renne, R.; Staskus, K.; Haase, A.; Ganem, D. A cluster of latently expressed genes in Kaposi’s sarcoma-associated herpesvirus. J. Virol. 1998, 72, 8309–8315.
52. Kedes, D.H.; Lagunoff, M.; Renne, R.; Ganem, D. Identification of the gene encoding the major latency-associated nuclear antigen of the Kaposi’s sarcoma-associated herpesvirus. J. Clin. Investig. 1997, 100, 2606–2610.
53. Rainbow, L.; Platt, G.M.; Simpson, G.R.; Sarid, R.; Gao, S.J.; Stoiber, H.; Herrington, C.S.; Moore, P.S.; Schulz, T.F. The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen. J. Virol. 1997, 71, 5915–5921.
54. Sadler, R.; Wu, L.; Forghani, B.; Renne, R.; Zhong, W.; Herndier, B.; Ganem, D. A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi’s sarcoma-associated herpesvirus. J. Virol. 1999, 73, 5722–5730.
55. Wen, K.W.; Damania, B. Kaposi sarcoma-associated herpesvirus (KSHV): Molecular biology and oncogenesis. Cancer Lett. 2010, 289, 140–150.
56. Pearce, M.; Matsumura, S.; Wilson, A.C. Transcripts encoding K12, v-FLIP, v-cyclin, and the microRNA cluster of Kaposi’s sarcoma-associated herpesvirus originate from a common promoter. J. Virol. 2005, 79, 14457–14464.
57. Wies, E.; Mori, Y.; Hahn, A.; Kremmer, E.; Sturzl, M.; Fleckenstein, B.; Neipel, F. The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells. Blood2008, 111, 320–327.
58. Ganem, D. KSHV and the pathogenesis of Kaposi sarcoma: Listening to human biology and medicine. J. Clin. Investig. 2010, 120, 939–949.
59. Lee, H.; Guo, J.; Li, M.; Choi, J.K.; deMaria, M.; Rosenzweig, M.; Jung, J.U. Identification of an immunoreceptor tyrosine-based activation motif of K1 transforming protein of Kaposi’s sarcoma-associated herpesvirus. Mol. Cell. Biol. 1998, 18, 5219–5228.
60. Lagunoff, M.; Majeti, R.; Weiss, A.; Ganem, D. Deregulated signal transduction by the K1 gene product of Kaposi’s sarcoma-associated herpesvirus. Proc. Natl. Acad. Sci. USA1999, 96, 5704–5709.
61. Van Dross, R.; Yao, S.; Asad, S.; Westlake, G.; Mays, D.J.; Barquero, L.; Duell, S.; Pietenpol, J.A.; Browning, P.J. Constitutively active K-cyclin/cdk6 kinase in Kaposi sarcoma-associated herpesvirus-infected cells. J. Natl. Cancer Inst. 2005, 97, 656–666.
62. Direkze, S.; Laman, H. Regulation of growth signalling and cell cycle by Kaposi’s sarcoma-associated herpesvirus genes. Int. J. Exp. Pathol. 2004, 85, 305–319.
63. Sarek, G.; Jarviluoma, A.; Moore, H.M.; Tojkander, S.; Vartia, S.; Biberfeld, P.; Laiho, M.; Ojala, P.M. Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency. PLoS. Pathog. 2010, 6, e1000818.
64. Liang, X.; Paden, C.R.; Morales, F.M.; Powers, R.P.; Jacob, J.; Speck, S.H. Murine gamma-herpesvirus immortalization of fetal liver-derived B cells requires both the viral cyclin D homolog and latency-associated nuclear antigen. PLoS Pathog. 2011, 7, e1002220.
65. Ye, F.C.; Zhou, F.C.; Xie, J.P.; Kang, T.; Greene, W.; Kuhne, K.; Lei, X.F.; Li, Q.H.; Gao, S.J. Kaposi’s sarcoma-associated herpesvirus latent gene vFLIP inhibits viral lytic replication through NF-kappaB-mediated suppression of the AP-1 pathway: A novel mechanism of virus control of latency. J. Virol. 2008, 82, 4235–4249.
66. Guasparri, I.; Keller, S.A.; Cesarman, E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J. Exp. Med. 2004, 199, 993–1003.
67. Israel, A. The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb. Perspect. Biol. 2010, 2, a000158.
68. Field, N.; Low, W.; Daniels, M.; Howell, S.; Daviet, L.; Boshoff, C.; Collins, M. KSHV vFLIP binds to IKK-gamma to activate IKK. J. Cell Sci. 2003, 116, 3721–3728.
69. Ye, F.; Lei, X.; Gao, S.J. Mechanisms of Kaposi’s Sarcoma-Associated Herpesvirus Latency and Reactivation. Adv. Virol. 2011, doi:10.1155/2011/193860.
70. McCormick, C.; Ganem, D. The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. Science 2005, 307, 739–741.
71. Lin, Y.T.; Kincaid, R.P.; Arasappan, D.; Dowd, S.E.; Hunicke-Smith, S.P.; Sullivan, C.S. Small RNA profiling reveals antisense transcription throughout the KSHV genome and novel small RNAs. RNA 2010, 16, 1540–1558.
72. Feldman, E.R.; Kara, M.; Coleman, C.B.; Grau, K.R.; Oko, L.M.; Krueger, B.J.; Renne, R.; van Dyk, L.F.; Tibbetts, S.A. Virus-encoded microRNAs facilitate gammaherpesvirus latency and pathogenesis in vivo. MBIO2014, 5, e00981–e00914.
73. Moody, R.; Zhu, Y.; Huang, Y.; Cui, X.; Jones, T.; Bedolla, R.; Lei, X.; Bai, Z.; Gao, S.J. KSHV microRNAs mediate cellular transformation and tumorigenesis by redundantly targeting cell growth and survival pathways. PLoS Pathog. 2013, 9, e1003857.
74. Suffert, G.; Malterer, G.; Hausser, J.; Viiliainen, J.; Fender, A.; Contrant, M.; Ivacevic, T.; Benes, V.; Gros, F.; Voinnet, O.; et al. Kaposi’s sarcoma herpesvirus microRNAs target caspase 3 and regulate apoptosis. PLoS Pathog. 2011, 7, e1002405.
75. Qin, Z.; Jakymiw, A.; Findlay, V.; Parsons, C. KSHV-Encoded MicroRNAs: Lessons for Viral Cancer Pathogenesis and Emerging Concepts. Int. J. Cell Biol. 2012, 2012, 603961.
76. Lacoste, V.; Judde, J.G.; Bestett, G.; Cadranel, J.; Antoine, M.; Valensi, F.; Delabesse, E.; Macintyre, E.; Gessain, A. Virological and molecular characterisation of a new B lymphoid cell line, established from an AIDS patient with primary effusion lymphoma, harbouring both KSHV/HHV8 and EBV viruses. Leuk. Lymphoma2000, 38, 401–409.
77. Ueda, K.; Sakakibara, S.; Ohsaki, E.; Yada, K. Lack of a mechanism for faithful partition and maintenance of the KSHV genome. Virus Res. 2006, 122, 85–94.
78. Collins, C.M.; Medveczky, P.G. Genetic requirements for the episomal maintenance of oncogenic herpesvirus genomes. Adv. Cancer Res. 2002, 84, 155–174.
79. Ye, F.C.; Zhou, F.C.; Yoo, S.M.; Xie, J.P.; Browning, P.J.; Gao, S.J. Disruption of Kaposi’s sarcoma-associated herpesvirus latent nuclear antigen leads to abortive episome persistence. J. Virol. 2004, 78, 11121–11129.
80. Wong, L.Y.; Wilson, A.C. Kaposi’s sarcoma-associated herpesvirus latency-associated nuclear antigen induces a strong bend on binding to terminal repeat DNA. J. Virol. 2005, 79, 13829–13836.
81. Lu, F.; Tsai, K.; Chen, H.S.; Wikramasinghe, P.; Davuluri, R.V.; Showe, L.; Domsic, J.; Marmorstein, R.; Lieberman, P.M. Identification of host-chromosome binding sites and candidate gene targets for Kaposi’s sarcoma-associated herpesvirus LANA. J. Virol. 2012, 86, 5752–5762.
82. Ballestas, M.E.; Kaye, K.M. Kaposi’s sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mediates episome persistence through cis-acting terminal repeat (TR) sequence and specifically binds TR DNA. J. Virol. 2001, 75, 3250–3258.
83. Cotter, M.A., 2nd; Subramanian, C.; Robertson, E.S. The Kaposi’s sarcoma-associated herpesvirus latency-associated nuclear antigen binds to specific sequences at the left end of the viral genome through its carboxy-terminus. Virology2001, 291, 241–259.
84. Barbera, A.J.; Chodaparambil, J.V.; Kelley-Clarke, B.; Joukov, V.; Walter, J.C.; Luger, K.; Kaye, K.M. The nucleosomal surface as a docking station for Kaposi’s sarcoma herpesvirus LANA. Science2006, 311, 856–861.
85. Si, H.; Verma, S.C.; Lampson, M.A.; Cai, Q.; Robertson, E.S. Kaposi’s sarcoma-associated herpesvirus-encoded LANA can interact with the nuclear mitotic apparatus protein to regulate genome maintenance and segregation. J. Virol. 2008, 82, 6734–6746.
86. Matsumura, S.; Persson, L.M.; Wong, L.; Wilson, A.C. The latency-associated nuclear antigen interacts with MeCP2 and nucleosomes through separate domains. J. Virol. 2010, 84, 2318–2330.
87. You, J.; Srinivasan, V.; Denis, G.V.; Harrington, W.J., Jr.; Ballestas, M.E.; Kaye, K.M.; Howley, P.M. Kaposi’s sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with bromodomain protein Brd4 on host mitotic chromosomes. J. Virol. 2006, 80, 8909–8919.
88. Ottinger, M.; Christalla, T.; Nathan, K.; Brinkmann, M.M.; Viejo-Borbolla, A.; Schulz, T.F. Kaposi’s sarcoma-associated herpesvirus LANA-1 interacts with the short variant of BRD4 and releases cells from a BRD4- and BRD2/RING3-induced G1 cell cycle arrest. J. Virol. 2006, 80, 10772–10786.
89. Xiao, B.; Verma, S.C.; Cai, Q.; Kaul, R.; Lu, J.; Saha, A.; Robertson, E.S. Bub1 and CENP-F can contribute to Kaposi’s sarcoma-associated herpesvirus genome persistence by targeting LANA to kinetochores. J. Virol. 2010, 84, 9718–9732.
90. Cotter, M.A., 2nd; Robertson, E.S. The latency-associated nuclear antigen tethers the Kaposi’s sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells. Virology1999, 264, 254–264.
91. Luger, K.; Mader, A.W.; Richmond, R.K.; Sargent, D.F.; Richmond, T.J. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature1997, 389, 251–260.
92. Zhou, Y.B.; Gerchman, S.E.; Ramakrishnan, V.; Travers, A.; Muyldermans, S. Position and orientation of the globular domain of linker histone H5 on the nucleosome. Nature1998, 395, 402–405.
93. Barbera, A.J.; Chodaparambil, J.V.; Kelley-Clarke, B.; Luger, K.; Kaye, K.M. Kaposi’s sarcoma-associated herpesvirus LANA hitches a ride on the chromosome. Cell Cycle2006, 5, 1048–1052.
94. Jha, H.C.; Upadhyay, S.K.; MahadeshPrasad, A.J.; Lu, J.; Cai, Q.; Saha, A.; Robertson, E.S. H2AX phosphorylation is important for LANA-mediated Kaposi’s sarcoma-associated herpesvirus episome persistence. J. Virol. 2013, 87, 5255–5269.
95. Doxsey, S.; Zimmerman, W.; Mikule, K. Centrosome control of the cell cycle. Trends Cell Biol. 2005, 15, 303–311.
96. Guse, A.; Carroll, C.W.; Moree, B.; Fuller, C.J.; Straight, A.F. In vitro centromere and kinetochore assembly on defined chromatin templates. Nature2011, 477, 354–358.
97. Johnson, V.L.; Scott, M.I.; Holt, S.V.; Hussein, D.; Taylor, S.S. Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congression. J. Cell Sci. 2004, 117, 1577–1589.
98. Saitoh, S.; Kobayashi, Y.; Ogiyama, Y.; Takahashi, K. Dual regulation of Mad2 localization on kinetochores by Bub1 and Dam1/DASH that ensure proper spindle interaction. Mol. Biol. Cell 2008, 19, 3885–3897.
99. Sun, Z.; Xiao, B.; Jha, H.C.; Lu, J.; Banerjee, S.; Robertson, E.S. Kaposi’s Sarcoma-Associated Herpesvirus-Encoded LANA Can Induce Chromosomal Instability through Targeted Degradation of the Mitotic Checkpoint Kinase Bub1. J. Virol. 2014, 88, 7367–7378.
100. Compton, D.A.; Szilak, I.; Cleveland, D.W. Primary structure of NuMA, an intranuclear protein that defines a novel pathway for segregation of proteins at mitosis. J. Cell Biol. 1992, 116, 1395–1408.
101. Harborth, J.; Wang, J.; Gueth-Hallonet, C.; Weber, K.; Osborn, M. Self assembly of NuMA: Multiarm oligomers as structural units of a nuclear lattice. EMBO J. 1999, 18, 1689–1700.
102. Du, Q.; Stukenberg, P.T.; Macara, I.G. A mammalian Partner of inscuteable binds NuMA and regulates mitotic spindle organization. Nat. Cell Biol. 2001, 3, 1069–1075.
103. Du, Q.; Macara, I.G. Mammalian Pins is a conformational switch that links NuMA to heterotrimeric G proteins. Cell 2004, 119, 503–516.
104. Kisurina-Evgenieva, O.; Mack, G.; Du, Q.; Macara, I.; Khodjakov, A.; Compton, D.A. Multiple mechanisms regulate NuMA dynamics at spindle poles. J. Cell Sci. 2004, 117, 6391–6400.
105. Gobert, G.N.; Hueser, C.N.; Curran, E.M.; Sun, Q.Y.; Glinsky, V.V.; Welshons, W.V.; Eisenstark, A.; Schatten, H. Immunolocalization of NuMA and phosphorylated proteins during the cell cycle in human breast and prostate cancer cells as analyzed by immunofluorescence and postembedding immunoelectron microscopy. Histochem. Cell Biol. 2001, 115, 381–395.
106. Sparks, C.A.; Fey, E.G.; Vidair, C.A.; Doxsey, S.J. Phosphorylation of NUMA occurs during nuclear breakdown and not mitotic spindle assembly. J. Cell Sci. 1995, 108, 3389–3396.
107. Zeng, C.; He, D.; Berget, S.M.; Brinkley, B.R. Nuclear-mitotic apparatus protein: A structural protein interface between the nucleoskeleton and RNA splicing. Proc. Natl. Acad. Sci. USA1994, 91, 1505–1509.
108. Merdes, A.; Cleveland, D.W. The role of NuMA in the interphase nucleus. J. Cell Sci. 1998, 111, 71–79.
109. Luderus, M.E.; den Blaauwen, J.L.; de Smit, O.J.; Compton, D.A.; van Driel, R. Binding of matrix attachment regions to lamin polymers involves single-stranded regions and the minor groove. Mol. Cell. Biol. 1994, 14, 6297–6305.
110. Du, Q.; Taylor, L.; Compton, D.A.; Macara, I.G. LGN blocks the ability of NuMA to bind and stabilize microtubules. A mechanism for mitotic spindle assembly regulation. Curr. Biol. 2002, 12, 1928–1933.
111. Haren, L.; Merdes, A. Direct binding of NuMA to tubulin is mediated by a novel sequence motif in the tail domain that bundles and stabilizes microtubules. J. Cell Sci2002, 115, 1815–1824.
112. Merdes, A.; Ramyar, K.; Vechio, J.D.; Cleveland, D.W. A complex of NuMA and cytoplasmic dynein is essential for mitotic spindle assembly. Cell1 996, 87, 447–458.
113. Yang, C.H.; Snyder, M. The nuclear-mitotic apparatus protein is important in the establishment and maintenance of the bipolar mitotic spindle apparatus. Mol. Biol. Cell1992, 3, 1259–1267.
114. Gueth-Hallonet, C.; Weber, K.; Osborn, M. NuMA: A bipartite nuclear location signal and other functional properties of the tail domain. Exp. Cell Res. 1996, 225, 207–218.
115. Verma, S.C.; Robertson, E.S. Molecular biology and pathogenesis of Kaposi sarcoma-associated herpesvirus. FEMS Microbiol. Lett. 2003, 222, 155–163.
116. Aravind, L.; Landsman, D. AT-hook motifs identified in a wide variety of DNA-binding proteins. Nucleic Acids Res. 1998, 26, 4413–4421.
117. Meehan, R.R.; Lewis, J.D.; Bird, A.P. Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res. 1992, 20, 5085–5092.
118. Nan, X.; Campoy, F.J.; Bird, A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell1997, 88, 471–481.
119. Young, J.I.; Hong, E.P.; Castle, J.C.; Crespo-Barreto, J.; Bowman, A.B.; Rose, M.F.; Kang, D.; Richman, R.; Johnson, J.M.; Berget, S.; et al. Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proc. Natl. Acad. Sci. USA2005, 102, 17551–17558.
120. Chahrour, M.; Jung, S.Y.; Shaw, C.; Zhou, X.; Wong, S.T.; Qin, J.; Zoghbi, H.Y. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science2008, 320, 1224–1229.
121. Yasui, D.H.; Peddada, S.; Bieda, M.C.; Vallero, R.O.; Hogart, A.; Nagarajan, R.P.; Thatcher, K.N.; Farnham, P.J.; Lasalle, J.M. Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes. Proc. Natl. Acad. Sci. USA2007, 104, 19416–19421.
122. Georgel, P.T.; Horowitz-Scherer, R.A.; Adkins, N.; Woodcock, C.L.; Wade, P.A.; Hansen, J.C. Chromatin compaction by human MeCP2. Assembly of novel secondary chromatin structures in the absence of DNA methylation. J. Biol. Chem. 2003, 278, 32181–32188.
123. Nikitina, T.; Ghosh, R.P.; Horowitz-Scherer, R.A.; Hansen, J.C.; Grigoryev, S.A.; Woodcock, C.L. MeCP2-chromatin interactions include the formation of chromatosome-like structures and are altered in mutations causing Rett syndrome. J. Biol. Chem. 2007, 282, 28237–28245.
124. Krithivas, A.; Fujimuro, M.; Weidner, M.; Young, D.B.; Hayward, S.D. Protein interactions targeting the latency-associated nuclear antigen of Kaposi’s sarcoma-associated herpesvirus to cell chromosomes. J. Virol. 2002, 76, 11596–11604.
125. Waldmann, T.; Scholten, I.; Kappes, F.; Hu, H.G.; Knippers, R. The DEK protein—An abundant and ubiquitous constituent of mammalian chromatin. Gene 2004, 343, 1–9.
126. Von Lindern, M.; Fornerod, M.; van Baal, S.; Jaegle, M.; de Wit, T.; Buijs, A.; Grosveld, G. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol. Cell. Biol. 1992, 12, 1687–1697.
127. Faulkner, N.E.; Hilfinger, J.M.; Markovitz, D.M. Protein phosphatase 2A activates the HIV-2 promoter through enhancer elements that include the pets site. J. Biol. Chem. 2001, 276, 25804–25812.
128. Fu, G.K.; Markovitz, D.M. Purification of the pets factor. A nuclear protein that binds to the inducible TG-rich element of the human immunodeficiency virus type 2 enhancer. J. Biol. Chem. 1996, 271, 19599–19605.
129. Fu, G.K.; Grosveld, G.; Markovitz, D.M. DEK, an autoantigen involved in a chromosomal translocation in acute myelogenous leukemia, binds to the HIV-2 enhancer. Proc. Natl. Acad. Sci. USA1997, 94, 1811–1815.
130. McGarvey, T.; Rosonina, E.; McCracken, S.; Li, Q.; Arnaout, R.; Mientjes, E.; Nickerson, J.A.; Awrey, D.; Greenblatt, J.; Grosveld, G.; et al. The acute myeloid leukemia-associated protein, DEK, forms a splicing-dependent interaction with exon-product complexes. J. Cell Biol. 2000, 150, 309–320.
131. Alexiadis, V.; Waldmann, T.; Andersen, J.; Mann, M.; Knippers, R.; Gruss, C. The protein encoded by the proto-oncogene DEK changes the topology of chromatin and reduces the efficiency of DNA replication in a chromatin-specific manner. Genes Dev. 2000, 14, 1308–1312.
132. Chua, P.; Roeder, G.S. Bdf1, a yeast chromosomal protein required for sporulation. Mol. Cell. Biol. 1995, 15, 3685–3696.
133. Florence, B.; Faller, D.V. You bet-cha: A novel family of transcriptional regulators. Front. Biosci. 2001, 6, D1008–D1018.
134. Jang, M.K.; Mochizuki, K.; Zhou, M.; Jeong, H.S.; Brady, J.N.; Ozato, K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell 2005, 19, 523–534.
135. Yang, Z.; Yik, J.H.; Chen, R.; He, N.; Jang, M.K.; Ozato, K.; Zhou, Q. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell 2005, 19, 535–545.
136. Sinha, A.; Faller, D.V.; Denis, G.V. Bromodomain analysis of Brd2-dependent transcriptional activation of cyclin A. Biochem. J. 2005, 387, 257–269.
137. Houzelstein, D.; Bullock, S.L.; Lynch, D.E.; Grigorieva, E.F.; Wilson, V.A.; Beddington, R.S. Growth and early postimplantation defects in mice deficient for the bromodomain-containing protein Brd4. Mol. Cell. Biol. 2002, 22, 3794–3802.
138. You, J.; Croyle, J.L.; Nishimura, A.; Ozato, K.; Howley, P.M. Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell 2004, 117, 349–360.
139. Pamblanco, M.; Poveda, A.; Sendra, R.; Rodriguez-Navarro, S.; Perez-Ortin, J.E.; Tordera, V. Bromodomain factor 1 (Bdf1) protein interacts with histones. FEBS Lett. 2001, 496, 31–35.
140. Kanno, T.; Kanno, Y.; Siegel, R.M.; Jang, M.K.; Lenardo, M.J.; Ozato, K. Selective recognition of acetylated histones by bromodomain proteins visualized in living cells. Mol. Cell 2004, 13, 33–43.
141. Dey, A.; Chitsaz, F.; Abbasi, A.; Misteli, T.; Ozato, K. The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc. Natl. Acad. Sci. USA2003, 100, 8758–8763.
142. Denis, G.V.; Vaziri, C.; Guo, N.; Faller, D.V. RING3 kinase transactivates promoters of cell cycle regulatory genes through E2F. Cell Growth Differ. 2000, 11, 417–424.
143. Platt, G.M.; Simpson, G.R.; Mittnacht, S.; Schulz, T.F. Latent nuclear antigen of Kaposi’s sarcoma-associated herpesvirus interacts with RING3, a homolog of the Drosophila female sterile homeotic (fsh) gene. J. Virol. 1999, 73, 9789–9795.
144. Mattsson, K.; Kiss, C.; Platt, G.M.; Simpson, G.R.; Kashuba, E.; Klein, G.; Schulz, T.F.; Szekely, L. Latent nuclear antigen of Kaposi’s sarcoma herpesvirus/human herpesvirus-8 induces and relocates RING3 to nuclear heterochromatin regions. J. Gen. Virol. 2002, 83, 179–188.
145. Haynes, S.R.; Dollard, C.; Winston, F.; Beck, S.; Trowsdale, J.; Dawid, I.B. The bromodomain: A conserved sequence found in human, Drosophila and yeast proteins. Nucleic Acids Res. 1992, 20, 2603.
146. Nomura, N.; Nagase, T.; Miyajima, N.; Sazuka, T.; Tanaka, A.; Sato, S.; Seki, N.; Kawarabayasi, Y.; Ishikawa, K.; Tabata, S. Prediction of the coding sequences of unidentified human genes. II. The coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by analysis of cDNA clones from human cell line KG-1. DNA Res. 1994, 1, 223–229.
147. Jones, M.H.; Numata, M.; Shimane, M. Identification and characterization of BRDT: A testis-specific gene related to the bromodomain genes RING3 and Drosophila fsh. Genomics1997, 45, 529–534.
148. Stedman, W.; Deng, Z.; Lu, F.; Lieberman, P.M. ORC, MCM, and histone hyperacetylation at the Kaposi’s sarcoma-associated herpesvirus latent replication origin. J. Virol. 2004, 78, 12566–12575.
149. Verma, S.C.; Choudhuri, T.; Kaul, R.; Robertson, E.S. Latency-associated nuclear antigen (LANA) of Kaposi’s sarcoma-associated herpesvirus interacts with origin recognition complexes at the LANA binding sequence within the terminal repeats. J. Virol. 2006, 80, 2243–2256.
150. Dheekollu, J.; Chen, H.S.; Kaye, K.M.; Lieberman, P.M. Timeless-dependent DNA replication-coupled recombination promotes Kaposi’s Sarcoma-associated herpesvirus episome maintenance and terminal repeat stability. J. Virol. 2013, 87, 3699–3709.
151. Purushothaman, P.; McDowell, M.E.; McGuinness, J.; Salas, R.; Rumjahn, S.M.; Verma, S.C. Kaposi’s Sarcoma-Associated Herpesvirus-Encoded LANA Recruits Topoisomerase IIbeta for Latent DNA Replication of the Terminal Repeats. J. Virol. 2012, 86, 9983–9994.
152. Sun, Q.; Tsurimoto, T.; Juillard, F.; Li, L.; Li, S.; de Leon Vazquez, E.; Chen, S.; Kaye, K. Kaposi’s sarcoma-associated herpesvirus LANA recruits the DNA polymerase clamp loader to mediate efficient replication and virus persistence. Proc. Natl. Acad. Sci. USA2014, 111, 11816–11821.
153. Green, C.M.; Erdjument-Bromage, H.; Tempst, P.; Lowndes, N.F. A novel Rad24 checkpoint protein complex closely related to replication factor C. Curr. Biol. 2000, 10, 39–42.
154. Lu, F.; Zhou, J.; Wiedmer, A.; Madden, K.; Yuan, Y.; Lieberman, P.M. Chromatin remodeling of the Kaposi’s sarcoma-associated herpesvirus ORF50 promoter correlates with reactivation from latency. J. Virol. 2003, 77, 11425–11435.
155. Lu, J.; Jha, H.C.; Verma, S.C.; Sun, Z.; Banerjee, S.; Dzeng, R.; Robertson, E.S. Kaposi’s sarcoma-associated herpesvirus-encoded LANA contributes to viral latent replication by activating phosphorylation of survivin. J. Virol. 2014, 88, 4204–4217.
156. Lu, J.; Verma, S.C.; Murakami, M.; Cai, Q.; Kumar, P.; Xiao, B.; Robertson, E.S. Latency-associated nuclear antigen of Kaposi’s sarcoma-associated herpesvirus (KSHV) upregulates survivin expression in KSHV-associated B-lymphoma cells and contributes to their proliferation. J. Virol. 2009, 83, 7129–7141.
157. Verma, S.C.; Lu, J.; Cai, Q.; Kosiyatrakul, S.; McDowell, M.E.; Schildkraut, C.L.; Robertson, E.S. Single molecule analysis of replicated DNA reveals the usage of multiple KSHV genome regions for latent replication. PLoS Pathog. 2011, 7, e1002365.
158. Verma, S.C.; Lan, K.; Choudhuri, T.; Cotter, M.A.; Robertson, E.S. An autonomous replicating element within the KSHV genome. Cell Host Microbe2007, 2, 106–118.
159. Chen, W.; Hilton, I.B.; Staudt, M.R.; Burd, C.E.; Dittmer, D.P. Distinct p53, p53: LANA, and LANA complexes in Kaposi’s Sarcoma-associated Herpesvirus Lymphomas. J. Virol. 2010, 84, 3898–3908.
160. Friborg, J., Jr.; Kong, W.; Hottiger, M.O.; Nabel, G.J. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature1999, 402, 889–894.
161. Krithivas, A.; Young, D.B.; Liao, G.; Greene, D.; Hayward, S.D. Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL cells. J. Virol. 2000, 74, 9637–9645.
162. Lan, K.; Kuppers, D.A.; Robertson, E.S. Kaposi’s sarcoma-associated herpesvirus reactivation is regulated by interaction of latency-associated nuclear antigen with recombination signal sequence-binding protein Jkappa, the major downstream effector of the Notch signaling pathway. J. Virol. 2005, 79, 3468–3478.
163. Lim, C.; Lee, D.; Seo, T.; Choi, C.; Choe, J. Latency-associated nuclear antigen of Kaposi’s sarcoma-associated herpesvirus functionally interacts with heterochromatin protein 1. J. Biol. Chem. 2003, 278, 7397–7405.
164. Ohsaki, E.; Ueda, K.; Sakakibara, S.; Do, E.; Yada, K.; Yamanishi, K. Poly(ADP-ribose) polymerase 1 binds to Kaposi’s sarcoma-associated herpesvirus (KSHV) terminal repeat sequence and modulates KSHV replication in latency. J. Virol. 2004, 78, 9936–9946.
165. Shamay, M.; Krithivas, A.; Zhang, J.; Hayward, S.D. Recruitment of the de novo DNA methyltransferase Dnmt3a by Kaposi’s sarcoma-associated herpesvirus LANA. Proc. Natl. Acad. Sci. USA2006, 103, 14554–14559.
166. Si, H.; Robertson, E.S. Kaposi’s sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function. J. Virol. 2006, 80, 697–709.
167. Viejo-Borbolla, A.; Kati, E.; Sheldon, J.A.; Nathan, K.; Mattsson, K.; Szekely, L.; Schulz, T.F. A Domain in the C-terminal region of latency-associated nuclear antigen 1 of Kaposi’s sarcoma-associated Herpesvirus affects transcriptional activation and binding to nuclear heterochromatin. J. Virol. 2003, 77, 7093-7100.
168. Viejo-Borbolla, A.; Ottinger, M.; Bruning, E.; Burger, A.; Konig, R.; Kati, E.; Sheldon, J.A.; Schulz, T.F. Brd2/RING3 interacts with a chromatin-binding domain in the Kaposi’s Sarcoma-associated herpesvirus latency-associated nuclear antigen 1 (LANA-1) that is required for multiple functions of LANA-1. J. Virol. 2005, 79, 13618-13629.
169. Hu, J.; Yang, Y.; Turner, P.C.; Jain, V.; McIntyre, L.M.; Renne, R. LANA binds to multiple active viral and cellular promoters and associates with the H3K4methyltransferase hSET1 complex. PLoS Pathog. 2014, 10, e1004240.
170. Mercier, A.; Arias, C; Madrid, A.S.; Holdorf, M.M.; Ganem, D. Site-Specific Association with Host and Viral Chromatin by Kaposi’s Sarcoma-Associated Herpesvirus LANA and Its Reversal during Lytic Reactivation. J. Virol. 2014, 88, 6762-6777.
171. Raghavan, M.; del Cid, N.; Rizvi, S.M.; Peters, L.R. MHC class I assembly: Out and about. Trends Immunol. 2008, 29, 436-443.
172. Tang, J.; Gordon, G.M.; Muller, M.G.; Dahiya, M.; Foreman, K.E. Kaposi’s sarcoma-associated herpesvirus latency-associated nuclear antigen induces expression of the helix-loop-helix protein Id-1 in human endothelial cells. J. Virol. 2003, 77, 5975-5984.
173. Guito, J.; Lukac, D.M. KSHV Rta Promoter Specification and Viral Reactivation. Front. Microbiol. 2012, 3, 30.
174. Sun, R.; Lin, S.F.; Gradoville, L.; Yuan, Y.; Zhu, F.; Miller, G. A viral gene that activates lytic cycle expression of Kaposi’s sarcoma-associated herpesvirus. Proc. Natl. Acad. Sci. USA1998, 95, 10866-10871.
175. Bu, W.; Palmeri, D.; Krishnan, R.; Marin, R.; Aris, V.M.; Soteropoulos, P.; Lukac, D.M. Identification of direct transcriptional targets of the Kaposi’s sarcoma-associated herpesvirus Rta lytic switch protein by conditional nuclear localization. J. Virol. 2008, 82, 10709-10723.
176. Deng, H.; Young, A.; Sun, R. Auto-activation of the rta gene of human herpesvirus-8/Kaposi’s sarcoma-associated herpesvirus. J. Gen. Virol. 2000, 81, 3043-3048.
177. Li, Q.; Zhou, F.; Ye, F.; Gao, S.J. Genetic disruption of KSHV major latent nuclear antigen LANA enhances viral lytic transcriptional program. Virology2008, 379, 234-244.
178. Campbell, M.; Izumiya, Y. Post-Translational Modifications of Kaposi’s Sarcoma-Associated Herpesvirus Regulatory Proteins—SUMO and KSHV. Front. Microbiol. 2012, 3, 31.
179. Bachman, K.E.; Rountree, M.R.; Baylin, S.B. Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. J. Biol. Chem. 2001, 276, 32282-32287.
180. Verma, S.C.; Cai, Q.; Kreider, E.; Lu, J.; Robertson, E.S. Comprehensive analysis of LANA interacting proteins essential for viral genome tethering and persistence. PLoS One2013, 8, e74662.
181. Sakakibara, S.; Ueda, K.; Nishimura, K.; Do, E.; Ohsaki, E.; Okuno, T.; Yamanishi, K. Accumulation of heterochromatin components on the terminal repeat sequence of Kaposi’s sarcoma-associated herpesvirus mediated by the latency-associated nuclear antigen. J. Virol. 2004, 78, 7299-7310.
182. Kim, K.Y.; Huerta, S.B.; Izumiya, C.; Wang, D.H.; Martinez, A.; Shevchenko, B.; Kung, H.J.; Campbell, M.; Izumiya, Y. Kaposi’s sarcoma-associated herpesvirus (KSHV) latency-associated nuclear antigen regulates the KSHV epigenome by association with the histone demethylase KDM3A. J. Virol. 2013, 87, 6782–6793.
183. Lu, J.; Verma, S.C.; Cai, Q.; Robertson, E.S. The single RBP-Jkappa site within the LANA promoter is crucial for establishing Kaposi’s sarcoma-associated herpesvirus latency during primary infection. J. Virol. 2011, 85, 6148–6161.
184. Lu, J.; Verma, S.C.; Cai, Q.; Saha, A.; Dzeng, R.K.; Robertson, E.S. The RBP-Jkappa binding sites within the RTA promoter regulate KSHV latent infection and cell proliferation. PLoS Pathog. 2012, 8, e1002479.
185. Klose, R.J.; Bird, A.P. Genomic DNA methylation: The mark and its mediators. Trends Biochem. Sci. 2006, 31, 89–97.
186. Gray, K.S.; Forrest, J.C.; Speck, S.H. The de novo methyltransferases DNMT3a and DNMT3b target the murine gammaherpesvirus immediate-early gene 50 promoter during establishment of latency. J. Virol. 2010, 84, 4946–4959.
187. Lu, F.; Day, L.; Gao, S.J.; Lieberman, P.M. Acetylation of the latency-associated nuclear antigen regulates repression of Kaposi’s sarcoma-associated herpesvirus lytic transcription. J. Virol. 2006, 80, 5273–5282.
188. Fujimuro, M.; Liu, J.; Zhu, J.; Yokosawa, H.; Hayward, S.D. Regulation of the interaction between glycogen synthase kinase 3 and the Kaposi’s sarcoma-associated herpesvirus latency-associated nuclear antigen. J. Virol. 2005, 79, 10429–10441.
189. Cha, S.; Lim, C.; Lee, J.Y.; Song, Y.J.; Park, J.; Choe, J.; Seo, T. DNA-PK/Ku complex binds to latency-associated nuclear antigen and negatively regulates Kaposi’s sarcoma-associated herpesvirus latent replication. Biochem. Biophys. Res. Commun. 2010, 394, 934–939.
190. Cheng, F.; Weidner-Glunde, M.; Varjosalo, M.; Rainio, E.M.; Lehtonen, A.; Schulz, T.F.; Koskinen, P.J.; Taipale, J.; Ojala, P.M. KSHV reactivation from latency requires Pim-1 and Pim-3 kinases to inactivate the latency-associated nuclear antigen LANA. PLoS Pathog. 2009, 5, e1000324.
191. Campbell, M.; Chang, P.C.; Huerta, S.; Izumiya, C.; Davis, R.; Tepper, C.G.; Kim, K.Y.; Shevchenko, B.; Wang, D.H.; Jung, J.U.; et al. Protein arginine methyltransferase 1-directed methylation of Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen. J. Biol. Chem. 2012, 287, 5806–5818.
192. Knipe, D.M.; Lieberman, P.M.; Jung, J.U.; McBride, A.A.; Morris, K.V.; Ott, M.; Margolis, D.; Nieto, A.; Nevels, M.; Parks, R.J.; et al. Snapshots: Chromatin control of viral infection. Virology2013, 435, 141–156.
193. Gunther, T.; Grundhoff, A. The epigenetic landscape of latent Kaposi sarcoma-associated herpesvirus genomes. PLoS Pathog. 2010, 6, e1000935.
194. Toth, Z.; Maglinte, D.T.; Lee, S.H.; Lee, H.R.; Wong, L.Y.; Brulois, K.F.; Lee, S.; Buckley, J.D.; Laird, P.W.; Marquez, V.E.; et al. Epigenetic analysis of KSHV latent and lytic genomes. PLoS Pathog. 2010, 6, e1001013.
195. Toth, Z.; Brulois, K.; Lee, H.R.; Izumiya, Y.; Tepper, C.; Kung, H.J.; Jung, J.U. Biphasic euchromatin-to-heterochromatin transition on the KSHV genome following de novo infection. PLoS Pathog. 2013, 9, e1003813.
196. Rossetto, C.C.; Pari, G. KSHV PAN RNA associates with demethylases UTX and JMJD3 to activate lytic replication through a physical interaction with the virus genome. PLoS Pathog. 2012, 8, e1002680.
197. He, M.; Zhang, W.; Bakken, T.; Schutten, M.; Toth, Z.; Jung, J.U.; Gill, P.; Cannon, M.; Gao, S.J. Cancer angiogenesis induced by Kaposi sarcoma-associated herpesvirus is mediated by EZH2. Cancer Res. 2012, 72, 3582–3592.
198. Verma, S.C.; Lan, K.; Robertson, E. Structure and function of latency-associated nuclear antigen. Curr. Top. Microbiol. Immunol. 2007, 312, 101–136.
199. Liang, D.; Hu, H.; Li, S.; Dong, J.; Wang, X.; Wang, Y.; He, L.; He, Z.; Gao, Y.; Gao, S.J.; et al. Oncogenic herpesvirus KSHV Hijacks BMP-Smad1-Id signaling to promote tumorigenesis. PLoS Pathog. 2014, 10, e1004253.
200. Verma, S.C.; Borah, S.; Robertson, E.S. Latency-associated nuclear antigen of Kaposi’s sarcoma-associated herpesvirus up-regulates transcription of human telomerase reverse transcriptase promoter through interaction with transcription factor Sp1. J. Virol. 2004, 78, 10348–10359.
201. Lim, C.; Sohn, H.; Gwack, Y.; Choe, J. Latency-associated nuclear antigen of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus-8) binds ATF4/CREB2 and inhibits its transcriptional activation activity. J. Gen. Virol. 2000, 81, 2645–2652.
202. Murakami, Y.; Yamagoe, S.; Noguchi, K.; Takebe, Y.; Takahashi, N.; Uehara, Y.; Fukazawa, H. Ets-1-dependent expression of vascular endothelial growth factor receptors is activated by latency-associated nuclear antigen of Kaposi’s sarcoma-associated herpesvirus through interaction with Daxx. J. Biol. Chem. 2006, 281, 28113–28121.
203. Radkov, S.A.; Kellam, P.; Boshoff, C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat. Med.2000, 6, 1121–1127.
204. Fujimuro, M.; Hayward, S.D. The latency-associated nuclear antigen of Kaposi’s sarcoma-associated herpesvirus manipulates the activity of glycogen synthase kinase-3beta. J. Virol. 2003, 77, 8019–8030.
205. Lim, C.; Gwack, Y.; Hwang, S.; Kim, S.; Choe, J. The transcriptional activity of cAMP response element-binding protein-binding protein is modulated by the latency associated nuclear antigen of Kaposi’s sarcoma-associated herpesvirus. J. Biol. Chem. 2001, 276, 31016–31022.
206. Cai, Q.L.; Knight, J.S.; Verma, S.C.; Zald, P.; Robertson, E.S. EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog. 2006, 2, e116.
207. Cai, Q.; Xiao, B.; Si, H.; Cervini, A.; Gao, J.; Lu, J.; Upadhyay, S.K.; Verma, S.C.; Robertson, E.S. Kaposi’s sarcoma herpesvirus upregulates Aurora A expression to promote p53 phosphorylation and ubiquitylation. PLoS Pathog. 2012, 8, e1002566.
208. Hume, A.J.; Kalejta, R.F. Regulation of the retinoblastoma proteins by the human herpesviruses. Cell Div. 2009, 4, e1.
209. Cousins, E.; Nicholas, J. Molecular biology of human herpesvirus 8: Novel functions and virus-host interactions implicated in viral pathogenesis and replication. Recent Results Cancer Res. 2014, 193, 227–268.
210. Liu, J.; Martin, H.; Shamay, M.; Woodard, C.; Tang, Q.Q.; Hayward, S.D. Kaposi’s sarcoma-associated herpesvirus LANA protein downregulates nuclear glycogen synthase kinase 3 activity and consequently blocks differentiation. J. Virol. 2007, 81, 4722–4731.
211. Liu, J.; Martin, H.J.; Liao, G.; Hayward, S.D. The Kaposi’s sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc. J. Virol. 2007, 81, 10451–10459.
212. Paudel, N.; Sadagopan, S.; Chakraborty, S.; Sarek, G.; Ojala, P.M.; Chandran, B. Kaposi’s sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with multifunctional angiogenin to utilize its antiapoptotic functions. J. Virol. 2012, 86, 5974–5991.
213. Paudel, N.; Sadagopan, S.; Balasubramanian, S.; Chandran, B. Kaposi’s sarcoma-associated herpesvirus latency-associated nuclear antigen and angiogenin interact with common host proteins, including annexin A2, which is essential for survival of latently infected cells. J. Virol. 2012, 86, 1589–1607.
214. Yang, J.; Li, X.; Li, Y.; Southwood, M.; Ye, L.; Long, L.; Al-Lamki, R.S.; Morrell, N.W. Id proteins are critical downstream effectors of BMP signaling in human pulmonary arterial smooth muscle cells. American J. Physiol. Lung Cell. Mol. Physiol. 2013, 305, L312–L321.
215. Cai, Q.; Cai, S.; Zhu, C.; Verma, S.C.; Choi, J.Y.; Robertson, E.S. A Unique SUMO-2-Interacting Motif within LANA Is Essential for KSHV Latency. PLoS Pathog. 2013, 9, e1003750.
216. Sun, R.; Liang, D.; Gao, Y.; Lan, K. Kaposi’s sarcoma-associated herpesvirus-encoded LANA interacts with host KAP1 to facilitate establishment of viral latency. J. Virol. 2014, 88, 7331–7344.
217. Zhang, L.; Zhu, C.; Guo, Y.; Wei, F.; Lu, J.; Qin, J.; Banerjee, S.; Wang, J.; Shang, H.; Verma, S.C.; et al. Inhibition of KAP1 enhances hypoxia-induced Kaposi’s sarcoma-associated herpesvirus reactivation through RBP-Jkappa. J. Virol. 2014, 88, 6873–6884.
218. Chang, P.C.; Fitzgerald, L.D.; van Geelen, A.; Izumiya, Y.; Ellison, T.J.; Wang, D.H.; Ann, D.K.; Luciw, P.A.; Kung, H.J. Kruppel-associated box domain-associated protein-1 as a latency regulator for Kaposi’s sarcoma-associated herpesvirus and its modulation by the viral protein kinase. Cancer Res. 2009, 69, 5681–5689.
219. Drane, P.; Ouararhni, K.; Depaux, A.; Shuaib, M.; Hamiche, A. The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes Dev. 2010, 24, 1253–1265.